HEALTHJun 9 · 13:38 UTCSEMAFORTom Chivers

GSK buys cancer drugmaker Nuvalent for $10B

GSK acquired cancer drugmaker Nuvalent for $10.6 billion, reflecting the rising significance of cancer in the pharmaceutical market. The move aims to leverage Nuvalent’s antibody therapies to compete with companies like Merck, as cancer becomes more prevalent and treatable due to aging populations and advancements in detection and treatment.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

GSKorganizationNuvalentorganizationMerckorganizationcancertopicantibody therapiestopicTom Chiversperson

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

BUSINESSJun 9 · 07:28 UTC
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
BUSINESSJun 9 · 07:28 UTC
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
BUSINESSJun 9 · 06:48 UTC
STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
BUSINESSJun 8 · 13:40 UTC
Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion
BUSINESSJun 9 · 07:37 UTC
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down